Web22 Feb 2024 · Second-line treatment with dolutegravir and recycled tenofovir and lamivudine is superior to protease inhibitor-based treatment using a new nucleoside … WebIntroduction. Second line antiretroviral therapy (ART) virologic failure is defined as patients who are on second-line regimen and have a high viral load level (>1,000 copies/mL) in two consecutive measurement after 6 months of treatment and repeat test after 3 months to decide second line treatment virologic failure. 1 It is well established that virological …
Antiretroviral treatment failure and associated factors among HIV ...
Web6 Jun 2024 · The factor accounting for the heterogeneity in rates of treatment failure on first-line ART, virological failure (VF) and switching to second-line ART are not clearly understood as the definition of the virological outcome varies across studies, but are thought to involve demographic, clinical and treatment factors [21, 24, 25, 30,31,32,33,34]. … WebThe efficacy and toxic effects of nucleoside reverse-transcriptase inhibitors (NRTIs) are uncertain when these agents are used with a protease inhibitor in second-line therapy for human... slc southern landscape \u0026 construction ltd
Scilit Article - First-line regimen failure of antiretroviral therapy ...
Web30 Dec 2024 · Treatment effects were similar with first- and second-line therapies (P = 0.16 for heterogeneity). A total of 35 participants in the dolutegravir group and 40 in the standard-care group had at least one serious adverse event (P = 0.53), and 73 and 86, respectively, had at least one adverse event of grade 3 or higher (P = 0.24). Web20 Apr 2024 · In The Lancet HIV, Nicholas I Paton and colleagues report the 96-week data of the randomised, non-inferiority NADIA trial comparing dolutegravir versus ritonavir-boosted darunavir and zidovudine versus tenofovir in second-line ART. The study was designed to be relevant to the settings in which treatment is delivered and was done at seven sites ... WebAppropriate second-line antiretroviral therapy for HIV infection is needed in resource-limited settings. In a comparison of three protease-inhibitor–based regimens in sub-Saharan … slc staff login